Tag Archives: NASDAQ:CLSD

Wedbush Reaffirms Their Buy Rating on Clearside Biomedical (CLSD)

In a report released today, Liana Moussatos from Wedbush maintained a Buy rating on Clearside Biomedical (NASDAQ: CLSD), with a price target of $29. The company’s shares opened today at $7.40. According to TipRanks.com, Moussatos is a 3-star analyst with

Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (NASDAQ: CLSD), Histogenics (NASDAQ: HSGX) and Masimo Corp (NASDAQ: MASI)

There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Clearside Biomedical (NASDAQ: CLSD), Histogenics (NASDAQ: HSGX) and Masimo Corp (NASDAQ: MASI) with bullish sentiments. Clearside Biomedical (NASDAQ: CLSD) In a report

Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (NASDAQ: CLSD) and Bluebird Bio (NASDAQ: BLUE)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (NASDAQ: CLSD) and Bluebird Bio (NASDAQ: BLUE) with bullish sentiments. Clearside Biomedical (NASDAQ: CLSD) In a report released today, Liana

Clearside Biomedical Received its Third Buy in a Row

After J.P. Morgan and Wedbush assigned a Buy rating to Clearside Biomedical in the last month, the company received another Buy, this time from Cowen & Co.. Analyst Boris Peaker reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD) yesterday.

Analysts Offer Insights on Healthcare Companies: Clearside Biomedical (NASDAQ: CLSD) and Agile Therapeutics (NASDAQ: AGRX)

There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Clearside Biomedical (NASDAQ: CLSD) and Agile Therapeutics (NASDAQ: AGRX) with bullish sentiments. Clearside Biomedical (NASDAQ: CLSD) Wedbush analyst Liana Moussatos reiterated a

Cowen & Co. Releases a Buy Rating on Clearside Biomedical

In a report released today, Boris Peaker from Cowen & Co. reiterated a Buy rating on Clearside Biomedical (NASDAQ: CLSD). The company’s shares opened today at $7.42. Peaker said: “This morning CLSD announced accrual completion of its Phase 1/2 DME